Bachem Holding AG – The Swiss-American Engine of Modern Medicine
The Quiet Swiss Giant Powering the Weight-Loss Drug Revolution
If you've read about breakthrough weight-loss peptides or new gene-silencing therapies, you've likely read about molecules made by a Swiss company called Bachem Holding AG. While big pharmaceutical companies grab the headlines, this quiet powerhouse is the backbone of modern medicine. Bachem doesn't develop its own drugs. Instead, it manufactures the complex active ingredients that make these medicines work—the "picks and shovels" of the pharmaceutical industry.
A Fifty-Year Journey: from Small Lab to Global Leader
Bachem's story began in 1971, when entrepreneur Peter Grogg founded the company in Liestal, near Basel, Switzerland. He started with just two employees and 50,000 Swiss Francs, focusing on peptide synthesis—the process of building short chains of amino acids that would later become essential ingredients in many life-saving medicines.
In 1977, the company moved to Bubendorf, and by 1978, Bachem produced its first peptides for use in medicines under strict Good Manufacturing Practice guidelines. Growth came quickly. By 1981, production capacity had tripled and the workforce had grown to 150 employees.
The company's first major international expansion came in 1987 with the entry into the U.S. market through Bachem Bioscience Inc. in Philadelphia. This was followed by sales and marketing centers in Germany and France throughout the late 1980s and early 1990s, establishing a strong European presence.
A pivotal moment arrived in 1996 when Bachem acquired the second-largest peptide manufacturer in the world and formed Bachem California, establishing a facility in Torrance that remains a key U.S. hub today. In 1998, the company went public, listing its shares on the SIX Swiss Exchange, and continued growing through acquisitions, including Peninsula Laboratories and Sochinaz SA, a Swiss manufacturer of active pharmaceutical ingredients.
By 2001, the company had 500 employees and sales reached 141 million Swiss Francs. In 2003, Bachem adopted a new legal holding structure to support its continued growth. The next decade saw further expansion, including a collaboration with GlyTech Inc. to develop new amino acids for treating multiple sclerosis and the acquisition of the American Peptide Company in 2015.
In 2016, Bachem commissioned a modern R&D and small-series production facility in Bubendorf, and the workforce exceeded 1,000 employees for the first time. Sales surpassed 200 million Swiss Francs that year. The company also expanded into Asia with the establishment of Bachem Japan K.K. in Tokyo.
Even during the COVID-19 pandemic, Bachem secured its supply of active ingredients and increased production in critical areas, with sales exceeding 400 million Swiss Francs for the first time.
Peter Grogg, who served as CEO for over 30 years until 2002 and as Chairman until 2012, remained honorary chairman until his passing in June 2025 at age 83. Under his leadership, Bachem grew from a two-person operation into a global market leader. His daughter, Nicole Grogg Hötzer, has served as Vice-Chairwoman of the Board since 2011.
Today, Bachem employs over 1,500 people at six locations worldwide, with its headquarters still in Bubendorf, Switzerland.
Understanding the Peptide Boom
To understand Bachem, you need to understand TIDES—the industry term for peptides and oligonucleotides. These fragile molecules are incredibly difficult to make, yet they're the foundation of today's most popular medicines, including blockbuster diabetes and obesity drugs called GLP-1 receptor agonists.
Bachem has spent over 50 years mastering the art of scaling production from tiny amounts in a lab to metric tons in giant automated facilities. The company is one of the world's leading specialists in this field, serving pharmaceutical and biotech companies across the entire drug development lifecycle.
What Bachem Makes: Products & Capabilities
Bachem's product portfolio spans the entire peptide and oligonucleotide value chain. The company doesn't sell finished drugs to patients—instead, it supplies the essential active ingredients and development services that drugmakers rely on.
Peptide APIs
Bachem manufactures peptide-based active ingredients for some of the world's most successful drugs. These include GLP-1 receptor agonists used in diabetes and weight-loss treatments, as well as peptides for oncology, rare diseases, and metabolic disorders.
Oligonucleotide APIs
Short strands of DNA and RNA that power gene-silencing therapies and next-generation genetic medicines. Bachem produces these highly complex molecules for clinical trials and commercial use, including treatments for rare genetic conditions.
Custom Peptide Synthesis
For researchers and biotech startups, Bachem offers custom peptide synthesis services—from milligram quantities for early discovery to gram-scale for preclinical studies. This includes modified peptides, labeled peptides, and peptide libraries for screening.
CDMO/CMO Services
Bachem provides full contract development and manufacturing services, including process development, scale-up, validation, and commercial production. This covers everything from early-stage clinical supply to large-scale commercial manufacturing under FDA and EMA regulations.
Peptide-Based Cosmetic Ingredients
Beyond medicine, Bachem supplies high-purity peptides for premium skincare and cosmetic products. These bioactive peptides are used in anti-aging creams, serums, and other personal care formulations.
Research Reagents
Bachem offers a wide catalog of amino acids, peptide synthesis reagents, resins, and building blocks used by pharmaceutical and academic researchers worldwide. These are essential tools for drug discovery and development.
🧪 Key therapeutic areas Bachem serves: Obesity & diabetes · Oncology · Rare diseases · Cardiovascular · Infectious diseases · Genetic disorders · Neurology
Financial Performance: Strong Growth, Heavy Investment
For investors, Bachem represents a classic high-growth story. The company's financial results for fiscal year 2025 tell a story of strong demand and smart execution:
⚙️ Massive expansion — Bachem invested CHF 332.6 million in 2025 alone, building new facilities to meet surging demand. For 2026, the company plans to invest more than CHF 400 million.
The GLP-1 Windfall and Market Volatility
The meteoric rise of weight-loss medications has driven monumental demand for Bachem. The company is a primary supplier to major pharmaceutical companies, and its order book remains at a very high level.
However, high-growth stocks come with risk. When there's bad news about a customer's drug, Bachem's stock can drop sharply. The company's premium stock valuation also makes it vulnerable to broader market downturns.
Expanding the American Footprint
To serve the world's most lucrative pharmaceutical market, Bachem maintains a growing presence in the United States, with two key generative medicine and peptide hubs in California:
- Torrance, California: FDA-approved clinical development hub with over 200 employees. Partners with U.S. biotech startups and research institutions, making small-to-medium batches for clinical trials.
- Vista, California: Large-volume commercial manufacturing of active pharmaceutical ingredients — mass-production on American soil.
Green Chemistry & Innovation
Making peptides is historically a chemically intense, wasteful process. Bachem has invested heavily in eco-friendly innovations:
MCSGP (Continuous Chromatography): Twin-column purification that recycles overlapping chemical fractions, boosting yields by up to 50% while cutting solvent use by as much as 75%.
TAPS (Tag-Assisted Peptide Synthesis): A liquid‑phase method using specialized tags that reduces hazardous solvent waste and enables cost‑efficient, high‑purity production.
What's Next?
Bachem is evolving from a pure contract development and manufacturing organization toward a contract manufacturing organization focused on industrial‑scale production. The company's new "Building K" at its Swiss headquarters is designed specifically for this large‑scale manufacturing.
The company's stated ambition is to reach sales north of CHF one billion and become the world‑leading specialist in peptides and oligonucleotides. For 2026, Bachem projects 35% to 45% sales growth.
🧬 The Bottom Line
Bachem is the ultimate gatekeeper in the modern drug market. While pharmaceutical companies take the clinical trial risks, Bachem focuses on the complex chemistry required to manufacture the actual cures. For long‑term investors, its heavy capital spending is simply the price of maintaining a highly profitable position in a booming market. The company is betting big on the future of peptide‑based medicine — and so far, that bet is paying off.